Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
NCT05426005
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer Stage IV
Mismatch Repair-deficient (dMMR)
Microsatellite Instability-high (MSI-H)
Interventions
DRUG:
Cadonilimab
Sponsor
Sun Yat-sen University